Discovering tomorrow's drugs with Artificial Intelligence
Kantify has built one of the world’s most advanced drug discovery engines.
Our AI technology, Sapian, scans 10 billion molecules a day to find what others miss: small molecules that are effective and safe - in hours, not months.
Our AI technology, Sapian, scans 10 billion molecules a day to find what others miss: small molecules that are effective and safe - in hours, not months.
Unlocking stalled discovery
An AI which serves patients
Built for low-data biology. Sapian prioritizes areas where traditional
data-hungry AI fails, such as rare diseases and difficult oncology.
It is validated across a wide variety of target families.
Reopening doors science had closed
We use Sapian not to speed up what’s already working - but to unlock the ideas that are stuck.
Sapian discovers novel causal targets as well as novel selective small molecules.
Also for unliganded targets.
An unprecedented scale
Laboratory high-throughput screening would require 274 years to process 10 billion compounds.
Sapian can screen 10 billion compounds in less than a day. A game-changing leap forward.
Segolene Martin
Chief Executive Officer
Kantify
When we first started getting the first lab validations of our drug discovery platform, Sapian, we couldn't believe how much of a leap we had made over traditional drug discovery approaches. What took giant pharmaceutical companies years, took us weeks, using a fraction of the resources.
We know today that Sapian is hugely powerful and has the potential to truly revolutionize human health. There's a great moral responsibility that comes with this realization. We think every day about how we can maximize the impact, for the good of all, of this incredible technology we continue to develop.
Sapian is a Rosetta Stone for drug discovery
Find better drugs with less work
Through experimental data, we've shown that Sapian has an
unprecedented ability to find effective modulators of any biological
target. On average, more than 25% molecules we test act on our
biological target of interest - a significant increase over classical
screens where fewer than 0.01% molecules show any promise.
Capable of treating more than a single disease
We have successfully used Sapian to tackle a wide variety of
diseases, including in the fields of oncology, neurology, muscular
diseases, and even plant health. This unprecedent breadth of ability
shows that Sapian has reached a new level of understanding of
novel biology and chemistry.
Design drugs with fewer side effects
One of Sapians' unique capabilities is to accurately predict the
pharmacodynamic and phamacokinetic profile of drugs - information that
is crucial to understand likely side effects of drugs. In doing so, we
can pro-actively select the most promising drugs before any chemical
synthesis happens.
Explore new frontiers of biological understanding
Sapian is starting to uncover a wide variety of novel biological
mechanisms and druggable targets of a wide variety of diseases. In doing
so, we create significant new opportunities for targeted therapies which
are safer and more effective.
Powering good at scale , drug after drug
Find out more about the drugs we are designing
We are developing a pipeline of small molecules and degraders in a
variety of disease areas such as neurology, neuromuscular diseases,
cardiology and oncology, and more.
Learn about the technology we are developing
Sapian, our AI drug discovery platform, helps us to discover and
design safe and effective small molecule drugs and targeted protein
degraders at a fraction of the cost and time required.
Get to know the people of Kantify
We are a mission driven company at the crossroads of Artificial
Intelligence and Biotechnology. We have strong values and focus on creating
breakthrough technological advancements to make a difference in patients'
lives.
Partner with us
Kantify has a strong culture of collaboration with biotech and
academic partners. Discover how to partner with Kantify and accelerate
or unlock your drug hunting project.
News
Updates about our projects, team and technologyKantify Appoints Diana Sarkees Avoo as Junior ML Engineer
Wed 29 Oct 2025
Kantify's Machine Learning team grows with the addition of a new team member
Kantify at Bio Europe 2025
Wed 29 Oct 2025
Meet the Kantify Exec Team at Bio Europe 2025
Kantify Reaches New Milestone in AI-Driven Drug Discovery
Wed 22 Oct 2025
10 Billion Molecules Analyzed Per Day and a Major Advance in a Rare Cancer
Kantify at the CONDOR Symposium on Sarcoma
Thu 11 Sep 2025
Kantify will participate at the annual event of the CONDOR Symposium which will focus on Microenvironment And Immunotherapy Of Sarcomas
Insights
Insights about drugs, biology, chemistry, and machine learningSapian leads to in vivo results in liposarcoma
Wed 22 Oct 2025
Kantify reports a preclinical proof-of-concept program in soft tissue sarcoma with a focus on liposarcoma
Sapian predicts targets of Paracetamol (Acetaminophen)
Wed 19 Feb 2025
Kantify publishes the AI-predicted targets of Paracetamol (Acetaminophen) and highlights possible mechanisms of action
Prostate cancer drug discovery: promising advance
Thu 12 Dec 2024
A collaboration between Kantify and Johns Hopkins School of Medicine leads to initial, promising pre-clinical results on metastatic prostate cancer